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An electronic nose in the discrimination
of patients with asthma and controls
Silvano Dragonieri, MD,a,c Robert Schot, BEng,a Bart J. A. Mertens, PhD,b Saskia Le
Cessie, PhD,b Stefanie A. Gauw, BN,a Antonio Spanevello, MD,d Onofrio Resta, MD,c
Nico P. Willard, PhD,e Teunis J. Vink, PhD,e Klaus F. Rabe, MD, PhD,a
Elisabeth H. Bel, MD, PhD,f and Peter J. Sterk, MD, PhDa,f Leiden, Eindhoven, and
Amsterdam, The Netherlands, and Bari and Cassano Murge, ItalyBackground: Exhaled breath contains thousands of volatile
organic compounds (VOCs) that could serve as biomarkers of
lung disease. Electronic noses can distinguish VOC mixtures by
pattern recognition.
Objective: We hypothesized that an electronic nose can
discriminate exhaled air of patients with asthma from healthy
controls, and between patients with different disease severities.
Methods: Ten young patients with mild asthma (25.1 6 5.9
years; FEV1, 99.9 6 7.7% predicted), 10 young controls (26.8
6 6.4 years; FEV1, 101.9 6 10.3), 10 older patients with severe
asthma (49.5 6 12.0 years; FEV1, 62.3 6 23.6), and 10 older
controls (57.3 6 7.1 years; FEV1, 108.3 6 14.7) joined a cross-
sectional study with duplicate sampling of exhaled breath with
an interval of 2 to 5 minutes. Subjects inspired VOC-filtered air
by tidal breathing for 5 minutes, and a single expiratory vital
capacity was collected into a Tedlar bag that was sampled by
electronic nose (Cyranose 320) within 10 minutes. Smellprints
were analyzed by linear discriminant analysis on principal
component reduction. Cross-validation values (CVVs) were
calculated.
Results: Smellprints of patients with mild asthma were fully
separated from young controls (CVV, 100%; Mahalanobis
distance [M-distance], 5.32), and patients with severe asthma
could be distinguished from old controls (CVV, 90%;
M-distance, 2.77). Patients with mild and severe asthma
could be less well discriminated (CVV, 65%; M-distance,
1.23), whereas the 2 control groups were indistinguishable
(CVV, 50%; M-distance, 1.56). The duplicate samples
replicated these results.
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856Conclusion: An electronic nose can discriminate exhaled breath
of patients with asthma from controls but is less accurate in
distinguishing asthma severities.
Clinical implication: These findings warrant validation of
electronic noses in diagnosing newly presented patients with
asthma. (J Allergy Clin Immunol 2007;120:856-62.)
Key words: Asthma mild, asthma severe, biomarkers, diagnosis,
electronic nose, exhaled breath, volatile organic compounds
In today’s clinical practice, asthma is diagnosed and
monitored by symptoms and physiological measurements,
including lung function tests and the assessment of
responses to inhaled pharmacological agents.1 These tests
have been internationally standardized and are generally
considered to be reliable. However, they are rather com-
plex, time-consuming, and not widely applicable, which
has limited the implementation of the required techniques
at all necessary levels of medical care.1 Therefore, there
is a need for new diagnostic methods in asthma that are
simple, fast, accurate, and cost-effective.
During the past decade, cellular and molecular tech-
niques have been added as novel options for diagnosis and
monitoring in asthma. This includes eosinophil counts in
induced sputum2 and nitric oxide in exhaled air.3 These
approaches have been validated, but only the latter seems
to have a realistic potential of widespread application
in clinical research and practice on the basis of its
simplicity.4
Nitric oxide may not be the only diagnostically relevant
molecule in exhaled breath. It is well known that exhaled
human breath contains thousands of volatile organic
compounds (VOCs) in gas phase, which can individually
be detected by gas chromatography and mass spectrom-
etry (GC-MS).5,6 These include mixtures of, for example,
hydrocarbons, such as formaldehyde, methanol, ethanol,
hydrogen sulfide, benzene, acetaldehyde, propanal, ace-
tone, dimethyl sulfide, isoprene, toluene, phenol, xylene,
and many others.6 Such VOCs can potentially be used
as noninvasive biomarkers of various biochemical path-
ways that are operative in health and disease. Interestingly,
it has been demonstrated that there is a link between
exhaled VOCs and human lung disease, in particular
regarding lung cancer.7,8 However, the requirement of
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CVV: Cross-validation value
FVC: Forced vital capacity
GC-MS: Gas chromatography and mass spectrometry
M-distance: Mahalanobis distance
PCA: Principal component analysis
SPT: Skin prick test
VOC: Volatile organic compound
GC-MS has thus far limited the medical applications of
this approach.
Electronic noses represent an innovative method of
VOCs sampling because these devices allow online
recognition of complex VOCs mixtures by composite
nanosensor arrays in combination with learning algo-
rithms.9 Each sensor represents different fractions of the
VOC mixture, and the arrays exhibit good discrimination
performance along with high sensitivity, short response
time, and reversible behavior.9 Hence, electronic noses
use an essentially different concept from GC-MS. They
principally follow an empirical approach, allowing the
distinction of ‘‘smell-prints’’ obtained from various gase-
ous sources by pattern recognition, providing discrimina-
tion of gas mixtures irrespective of the individual
molecular components.10 The first proof of concept stud-
ies of electronic noses in respiratory medicine have
provided high accuracy in the ex vivo classification of
bacterial infection11-13 and promising discrimination of
exhaled breath obtained from patients with lung cancer
and controls.14
In the current study, we postulated that an electronic
nose can discriminate exhaled breath of patients with
asthma from healthy controls. Our aim was to test this
hypothesis by a cross-sectional study comparing patients
with an established diagnosis of asthma with healthy
controls. As a secondary aim, we examined whether an
electronic nose can distinguish different degrees of asthma
severity, and whether these classifications are reproduc-
ible when performing repeated measurements.
METHODS
Subjects
A total number of 40 subjects volunteered to participate to this
study. All the subjects were nonsmoking adults (18-75 years) without
any other acute or chronic disease than asthma. The study population
included 4 groups of subjects based on current standard diagnostic
procedures1: patients with intermittent-mild asthma and patients with
moderate-severe persistent asthma, each with their own healthy con-
trol group. Patients were recruited among those visiting the outpatient
clinic of the Leiden University Medical Center, whereas controls
were recruited by advertisements in the hospital, the university, and
public newspapers. Patients on medications other than short-acting
or long-acting b2-agonists and/or inhaled steroids or those who had
a history of upper or lower respiratory tract infection during the 4
weeks before to the measurements were excluded from the study.
The mild asthma group was composed of 10 patients with epi-
sodic chest symptoms, prebronchodilator FEV1 >80% predicted,documented reversibility in FEV1 by 400 mg inhaled salbutamol
>12% predicted or airway hyperresponsiveness (PC20 methacholine
< 8 mg/mL),15 atopy by positive skin prick tests (SPTs) in response to
common airborne allergen or by RAST, treatment by as necessary use
of inhaled short-acting b2-agonists only, no use of inhaled corticoste-
roids for 3 months before the study, and no exacerbations (requiring
oral steroid therapy) during the past 12 months.
The severe asthma group consisted of 10 patients who had
episodic or chronic chest symptoms, documented reversibility for
FEV1 >12% predicted or PC20 methacholine (<8 mg/mL),
15 positive
SPTs or positive RAST test, need of high doses of inhaled corticoste-
roids (1000 mg/d beclomethasone or equivalent) and long-acting
b2-agonists for more than 12 months, and at least 1 asthma exacerba-
tion requiring oral steroid therapy during the past 12 months.
The 2 control groups also had 10 subjects each with a negative
history of chest symptoms, prebronchodilator FEV1 >80% predicted,
and FEV1/forced vital capacity (FVC) >70%, absence of atopy by
negative SPTs or RASTs, and absence of airway hyperresponsive-
ness (PC20 methacholine > 8 mg/mL). The 2 control groups differed
with respect to age (18-45 years and 46-70 years, respectively) to be
compatible with the different age ranges that were observed in the
2 asthma groups of the study.
The study was approved by the Leiden University Medical Center
Ethics Committee, and all the subjects gave their written informed
consent.
Study design
The study had a cross-sectional case-control design with 2 visits
within a 10-day period. The first day was a screening day to check all
the inclusion and exclusion criteria. On the second day, exhaled
breath was collected in duplicate and sampled by the electronic nose.
Lung function
Spirometry (Masterlab Jaeger, Hoechberg, Germany) was per-
formed by a trained lung function technician according to the latest
recommendations,16 and the FEV1 and FVC were measured before
and 20 minutes after 400 mg inhaled salbutamol per metered dose in-
haler with a spacer (Volumatic, GSK, Brentford, United Kingdom
[UK]). Airway hyperresponsiveness was assessed by methacholine
challenge tests performed by the tidal breathing method, using dou-
bling inhaled doses (0.6-80 mmol/mL) at 5-minute intervals, until
the PC20 was reached.
15 Patients withheld short-acting b2 agonists
for >8 hours and long-acting b2 agonists for >12 hours before all
lung function measurements.
SPT
Skin prick tests were performed by using a standardized set
of 12 common airborne allergen extracts (ALK-Abello´, Hørsholm,
Denmark). Atopy was indicated by positivity (>3 mm wheal) to
1 or more allergens or by positive RAST.
Exhaled breath collection
The patients breathed through a mouthpiece with the nose
clipped into a 2-way nonrebreathing valve (Hans Rudolph 2700,
Hans Rudolph, Kansas City, Mo) with an inspiratory VOC filter
(A2, North Safety, Middelburg, NL) and an expiratory silica reservoir
to dry the expired air. The breathing maneuvers were based on vali-
dation experiments in our laboratory. After 5 minutes of equilibration
by tidal breathing with VOC-filtered air, the expiratory port was con-
nected to a 10-L Tedlar bag. The subject then performed an inspira-
tory capacity maneuver and exhaled the full expiratory vital
capacity into the bag with an expiratory resistance of 20 cmH2O to
close the soft palatum and to obtain an expiratory flow of 0.1 to 0.2
L/s. Within 10 minutes, the bag was connected to the electronic
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of the electronic nose, which represents the smellprint of a VOC mixture in exhaled breath of a single
volunteer with asthma.nose, followed by 1 minute of bag sampling in parallel with a second
Tedlar bag containing background VOC-filtered room air. All sub-
jects performed these maneuvers in duplicate by repeating the same
procedure after 2 to 5 minutes of resting.
Electronic nose
Exhaled breath samples were analyzed by a commercially avail-
able handheld electronic nose (Cyranose 320; Smith Detections,
Pasadena, Calif) with a nanocomposite array of 32 organic polymer
sensors.9 When the sensors are exposed to a mixture of VOCs the pol-
ymers are swelling, which induces a change in their electrical resis-
tance. The raw data are captured as the changes in resistance of
each of the 32 sensors in an onboard database, producing a distribu-
tion (smellprint; Fig 1) that describes the VOC mixture and that can
be used for pattern-recognition algorithms.
Exploration of specific VOCs in exhaled breath was performed by
sampling 1 L gas from the Tedlar bag through an adsorption tube
filled with Tenax GR (Scientific Instruments Services, Ringoes, NJ).
After sampling, the analytes were collected in a cryo-trap for refocus-
ing and subsequently injected into a gas chromatography column
(HP 5890 series II, Hewlett Packard, Palo Alto, Calif) and identified
by mass spectrometry (HP 5972 MSD, Hewlett Packard), using a cal-
ibration mixture to check average sensitivity.
Breathing maneuvers
Exhaled breath was collected by an expiratory vital capacity
maneuver after 5 minutes of tidal breathing with VOC-filtered room
air. We validated the breathing maneuvers by 3 preliminary exper-
iments to examine the effects of (1) inspiring VOC-filtered air, (2)
expiratory lung volume, and (3) expiratory flow. First, we examined
whether previous steady-state washin of VOC-filtered air is required,
or whether a single inspiration with VOC-filtered air suffices
preceding the collection of exhaled breath. Ten nonsmoking healthy
subjects (mean6 SD age, 35.26 10.1 years) performed 2 maneuvers
in random order with a 30-minute interval: equilibration withinspiratory VOC-filtered air by 5 minutes of tidal breathing or by
1 single inspiratory VC. The results were analyzed by principal com-
ponent analysis (PCA) and canonical discriminant analysis. The
smellprints obtained by the single inspiratory VC clustered distinctly
from those after 5 minutes of washin (cross-validation value, 95%;
Mahalanobis distance [M-distance], 4.24), indicating that a single in-
spiration of VOC-free air is not sufficient to equilibrate the exhaled
breath VOCs. This led us to choosing the 5-minute tidal washin
method. Second, we investigated whether collecting an expiratory
VC and expiratory tidal breaths provided the same smellprints.
This was also addressed in 10 nonsmoking healthy subjects (age,
39.6 6 11.7 years) for whom a single expiratory VC and 1-minute
tidal breaths were collected in random order with a 30-minute
interval. The PCA data showed that tidal breath samples could be
discriminated from expiratory VC samples (cross-validation, 85%;
M-distance, 2.51). We chose to use the single expiratory VC sam-
pling on the basis of the relatively smaller contribution of the anatom-
ical dead space. Third, we examined the possible influence of
expiratory flow during expiratory VC sampling in 10 nonsmoking
healthy subjects (age, 29.4 6 7.5 years) by using 0.1 to 0.2 L/s and
0.3 to 0.5 L/s in a random order with a 30-minute interval. The smell-
prints could not be discriminated well (cross-validation value, 65%;
M-distance, 1.17), suggesting a limited influence of expiratory flow
within this flow range. For our studies, we chose to standardize
flow at 0.1 to 0.2 L/s.
Data analysis
First, the smellprints were analyzed online by the on-board
learning software of the Cyranose 320. Subsequently, an offline con-
firmatory analysis was performed by double cross-validatory imple-
mentation of linear discriminant analysis on principal component
reduction using Matlab software (version 7; MathWorks Benelux,
Gouda, NL) as previously described.17 The data were processed
through Savitzky-Golay filtering and baseline correction.18 Then
they were analyzed by PCA to reduce the data from 32 individual
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Mild asthma Severe asthma Younger controls Older controls
No. of patients 10 10 10 10
Age (y) 25.1 6 5.9 49.5 6 12.0 26.8 6 6.4 57.3 6 7.1
Sex, male/female 1/9 8/2 2/8 4/6
FEV1 prebronchodilator, % predicted 99.9 6 7.7 62.3 6 23.6 101.9 6 10.3 108.3 6 14.7
FEV1 postbronchodilator, % predicted 111.9 6 9.2 74.3 6 21.8 ND ND
FVC, % predicted 109 6 8.1 80.9 6 17.3 101.9 6 7.2 102.6 6 17.4
ND, Not determined.
*Values are expressed as means 6 SDs.H
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capturing the largest variance in the dataset.19 PCA was used as an
exploratory analysis and was plotted in 2-dimensional or pseudo–
3-dimensional graphs to visualize between-group separations. Once
the PCA factors had been calculated, these factors were used to per-
form a linear canonical discriminant analysis for the construction of
a pattern recognition algorithm by maximizing the ratio of pooled
within-class scatter to between-group distance. The online software
calculated a cross-validation estimate of error: the cross-validation
value (CVV).20 M-distance was used to quantify the discrimination
between 2 sample groups.19 The M-distance provides the nonsimilar-
ity of a set of values derived from 2 samples. It takes the sample
variability into account and reflects the distance between group
means in units of standard deviations. The M-distance value and
the ability to discriminate are directly related, so that M-distance
values >3 are indicative of high probability of discrimination
(P < .01).
RESULTS
The subject characteristics of the 4 groups are described
in Table I. Patients with severe asthma were older than
patients with mild asthma (P < .01), which was the reason
for using 2 control groups with ages below and above
45 years, respectively. Two samples of exhaled air could
be obtained in all subjects.
First, we examined whether exhaled breath from
patients with asthma could be discriminated from controls.
The plots of the online PCA of the smellprints obtained
from the first bags in the patients and controls are shown in
Fig 2. Smellprints of patients with mild asthma were sep-
arated from those of the young controls (Fig 2, upper left).
Subsequent canonical discriminant analysis demonstrated
a cross-validation of 100% correct with a M-distance of
5.32. Similarly, smellprints from severe asthmatics could
be distinguished from those of old controls (Fig 2, upper
right). The cross-validation value was 90% correct with
a M-distance of 2.77.
However, discriminant analysis could discriminate less
well smellprints from patients with mild and severe
asthma (Fig 2, lower left). This led to a cross-validation
value of 65% correct and a M-distance of 1.23. There
was no difference in smellprints between the 2 control
groups (Fig 2, lower right), with a cross-validation value
of 50% and a M-distance of 1.56.
Analysis of exhaled air from the second bags replicated
these results (patients with mild asthma vs young controls:CVV, 100%; M-distance, 4.86; patients with severe
asthma vs old controls: CVV, 95%; M-distance, 5.72;
patients with mild asthma vs patients with severe asthma:
CVV, 60%; M-distance, 1.87; old controls vs young
controls: CVV, 60%; M-distance, 1.20).
The offline discriminant analysis on PCA reduction
using double cross-validation confirmed the onboard
discrimination between the groups (data not shown).
Explorative GC-MS analysis showed that the predomi-
nant VOCs (>15 ng/L) in asthma were 4-methyloctane,
2,4-dimethylheptane, isopropanol, toluene, isoprene, al-
kane, acetic acid, acetone, 2,6,11-trimethyl dodecane,
3,7-dimethyl undecane, and 2,3-dimethyl heptane.
DISCUSSION
Our study shows that an electronic nose can discrim-
inate exhaled breath of patients with asthma from healthy
controls. This distinction was replicated when analyzing
exhaled air from repeated samples. However, the elec-
tronic nose could not adequately discriminate mild from
severe asthma. These findings indicate that the mixture of
exhaled volatile organic compounds is different in asthma
compared with controls. Our findings warrant further
validation of electronic noses regarding their ability to
correctly identify newly presented patients with asthma.
To our knowledge, this is the first study using pattern
analysis of exhaled VOC mixtures by an electronic nose in
the field of asthma. Interestingly, we observed a complete
separation of smellprints between patients with mild
asthma and healthy controls as well as between patients
with severe asthma and controls. This was confirmed
when using duplicate measurements. To date, electronic
noses have been used in a variety of medical fields,
including the detection of sinusitis, cerebrospinal fluid
leak, urinary tract infections, bacterial vaginosis, and
diabetes mellitus.10 The application of electronic noses
in respiratory medicine showed moderate sensitivity but
high specificity in the detection of lung cancer from
exhaled breath14 and high accuracy in the in vitro diagno-
sis of Mycobacterium tuberculosis infections.13 Recent
studies further suggest that an electronic nose may be ap-
plicable in the diagnosis of ventilator-associated pneumo-
nia.21,22 Therefore, the VOCs present in the exhaled breath
may become a powerful source of biomarkers for the diag-
nosis of respiratory diseases, including asthma.
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smellprints between patients with mild asthma (diamonds) from their controls (squares, upper left), patients
with severe asthma (triangles) from their controls (bullets, upper right), patients with mild asthma (diamonds)
from patients with severe asthma (triangles, lower left), and young controls (squares) from older controls
(bullets, lower right).In our study, particular attention was paid to meth-
odologic aspects such as the selection of patients and
controls. All the patients were well characterized by
using subjective and objective criteria of the presence
and severity of atopic asthma.1 This included the pres-
ence of symptoms, reversible airways obstruction or air-
ways hyperresponsiveness to methacholine, and positive
SPTs. The controls of the 2 asthma groups were care-
fully screened to exclude all these features. The down-
side of this strict selection is that we cannot deduce
the separate contributions of atopy, lung function, and
hyperresponsiveness to the current discrimination. This
requires studies focused on subphenotyping. Smokers
and exsmokers were excluded because tobacco smoking
may well change the exhaled VOCs profile. However,
we had an imbalance in sex between the asthma groups
and cannot exclude that this affected the exhaled breathmolecular profiles. Furthermore, patients with mild and
severe asthma were selected on the basis of their medi-
cation usage. The mild asthma group was free of ste-
roids, whereas the severe asthma group was taking
inhaled corticosteroids and long-acting bronchodilators.
We cannot exclude that this (inevitable) difference in
drug regimen affected the VOCs profiles. However, the
electronic nose was not able to make a clear distinction
between mild and severe asthma. This may suggest that
drug usage is not a major determinant of exhaled breath
smellprints.
By using sample sizes of 10 subjects per group, the
electronic nose was able to make a full separation between
patients with asthma and controls (Fig 2). However, our
results suggest that higher sample sizes may be required
to obtain optimal training sets for electronic noses in pa-
tients with various severities of asthma. Finally, it seems
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cident or by error, because the duplicate samples led to
the closely similar results. Moreover, offline statistics17
confirmed the onboard analysis of the smellprints.
The sampling technique and breathing maneuvers were
optimized by pilot experiments. The measurements were
made in the same room with fixed temperature and
humidity. We dried the exhaled breath through a silica
filter to limit the influence of variable humidity on the
sensor signals. In addition, we made an attempt to avoid
any acute effects by food, coffee, or other drinks by not
allowing those during the 2 hours before the test. Finally,
our pilot experiments showed that the conditioning of
inspiratory air and the expiratory breathing maneuver both
influence the VOC pattern. The 5-minute steady-state
washin with VOC-free air was based on recommendations
for helium washin during lung volume measurements. It
cannot be excluded that this needs to be prolonged in
patients with severe airways obstruction. Our experiments
indicate that careful methodological standardization is
required for exhaled breath analysis by electronic nose.
How can the present findings be interpreted? GC-MS
analysis has shown that human exhaled breath contains
more than 3000 different VOCs.5,6 When using an inspi-
ratory VOC filter, the detected VOCs are most likely
derived from physiologic and pathophysiologic metabolic
pathways.5,6 These can arise from the airways and the
lungs or can represent systemic metabolites from else-
where in the body. Interestingly, before the application
of electronic noses, GC-MS analysis had already demon-
strated changes in specific VOCs in exhaled breath from
patients with lung cancer that are compatible with in-
creased production of reactive oxygen species and en-
hanced alkane metabolism by cytochrome P450.23
Chronic airways inflammation in asthma may change sev-
eral metabolic pathways that affect molecular markers in
exhaled breath.24 For instance, asthma is associated with
elevated levels of pentane25 in exhaled air, and with in-
creased concentrations of markers of oxidative stress26
and eicosanoids in exhaled breath condensate.27 It remains
to be established whether such markers are associated
with airways inflammation and airway remodeling in
asthma,28,29 which indeed has been reported recently.27
It needs to be emphasized that our study does not reveal
which specific VOCs are responsible for the discrimina-
tion of exhaled breath between patients with asthma and
controls. Our explorative GC-MS analysis showed the
presence of similar VOCs in asthma compared with
normal subjects6 or patients with lung cancer.14 However,
the determination of the specific, discriminative VOC con-
centrations between these diseases will require subsequent
studies. The electronic nose that we used detects VOC
mixtures with a polymer nanocomposite sensor array.9
Each sensor signal represents partly different fractions of
the complete VOC mixture on the basis of, for example,
molecular mass, shape, dipole moment, and hydrogen
binding capacity.14 Therefore, unlike GC-MS, an elec-
tronic nose principally does not chemically identify and
separate VOCs.9,30 Hence, the high relatively differentialresistance in sensor 9 (Fig 1) represents a mixture of
VOCs. Whether it contributes to the discrimination be-
tween patient groups depends on any differences in this
signal between the groups and its subsequent selection
by the PCA. Therefore, pattern recognition of smellprints
by electronic noses is purely based on a statistical ap-
proach, providing empirical evidence. Such procedure is
hypothesis-free and potentially powerful. It resembles
other high-throughput methods that are based on the anal-
ysis of molecular profiles of complex biological samples
by a single measurement (omics techniques).31 Interest-
ingly, the principle of electronic noses exactly mirrors
biological olfaction in mammals, in which multisensitive
olfactory receptor cells appear to be coupled to pattern rec-
ognition systems in the brain, leading to unique odors.32
Hence, our current observations by using an electronic
nose system can be considered complementary to GC-
MS analysis and warrant further studies by GC-MS to
identify the critical VOCs.
What are the clinical implications of our findings? The
electronic nose appears to be able to discriminate exhaled
breath from well characterized subjects with and without
asthma. Such discrimination of established cases and
controls represents the first step in the cross-sectional
validation of diagnostic tests.33 Our data warrant an exter-
nal validation of the electronic nose by testing its diagnos-
tic accuracy in a sample of newly presented patients with
various severities and subcategories of asthma. Such study
should be performed according to international recom-
mendations.34 If successful, electronic noses have the po-
tential to become convenient devices for physicians and
nurses for handheld, noninvasive, and rapid diagnosis of
asthma. In addition, validation of electronic noses in other
respiratory diseases, such as chronic obstructive pulmo-
nary disease or lung cancer, seems to be mandatory.14,35
We thank the patients for volunteering for this study and Christa
Assink, MSc, and Simone Hashimoto, MD, for helping recruit the
patients. We also thank Mr H. H. Knobel (Philips Research) for his
careful experiments with GC-MS.
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